Geistlich launches new collagen membrane at the IOS

At the International Osteology Symposium (IOS) in Vienna, Geistlich Pharma AG (Geistlich) launched the advanced collagen membrane Geistlich Bio-Gide® Forte for the European market. The launch is part of the company's global portfolio expansion, which includes new technologies, strategic partnerships, and targeted acquisitions. At the same time, Geistlich is expanding its initiatives to support the next generation.

Geistlich is a global leader dedicated to advancing regenerative medicine. The company has been the world market leader in the field of regenerative dentistry for many years. In addition, Geistlich is committed to providing comprehensive support to clinicians in the field of regenerative medicine through scientific research, innovative developments as well as educational programmes. Geistlich is a Swiss family-owned company with tradition since 1851. With 15 subsidiaries and 120 distributors, the company reaches over 100 markets and employs around 900 people.

This year's International Osteology Symposium was dedicated to Geistlich's 175th anniversary. This milestone year marks the company's expansion into new fields of regenerative medicine and the launch of 20 new products in over 40 countries. Among them is the advanced collagen membrane Geistlich Bio-Gide® Forte. Following its successful introduction in the United States and highly positive feedback from clinical practice, it is now also available in Europe. Geistlich Bio-Gide® Forte builds on proven Geistlich technology and offers increased strength, improved stability, and easy handling. The membrane's strength was demon-



01 © Geistlich


02 © Geistlich

01
Attendees celebrate Geistlich's 175th anniversary.

02
Two of the three winners of the Case Competition on stage at the Geistlich Corporate Forum.



© Geistlich 03

03
From left to right: Diego Gabathuler (CEO of Geistlich), Viraj Patel (Winner, Rising Stars Case Competition), Roberto Ledergerber (Winner, Rising Stars Case Competition), Frank Schwarz (President, Osteology Foundation), Nadja Nänni (Mentor, Next Generation Roundtable programme), Lorenzo Fiscalini (Winner, Rising Stars Case Competition), Dr Mark Spilker (CSO of Geistlich).

*The articles in this category are provided by the manufacturers or distributors and do not reflect the opinion of the editorial team.

“As a Swiss family-owned regenerative technology company, responsibility and pioneering spirit is in our DNA. Our pioneering spirit will drive continuous innovation. And, responsibility for patients, for our partners, for science and for quality, [...]”



04 © Geistlich



05 © Geistlich

04
Pack shot of Geistlich Bio-Gide® Forte.

05
Product image of Geistlich Bio-Gide® Forte.

strated in a load test at the IOS: 1,445 studies document the performance of the Geistlich Bio-Gide® technology, a scientific foundation of evidence equivalent to around four kilogrammes of paper, which Geistlich Bio-Gide® Forte can hold.

Tradition and expertise

At the IOS booth, visitors were able to immerse themselves in Geistlich’s rich history. What began in 1851 as Switzerland’s first glue factory evolved into a pioneer in medical regeneration thanks to scientific curiosity and expertise in bone and tissue processing. “As a Swiss family-owned regenerative technology company, responsibility and pioneering spirit is in our DNA. Our pioneering spirit will drive



06 © OEMUS MEDIA AG

06
Geistlich’s booth at the Osteology Symposium 2026 in Vienna.

*The articles in this category are provided by the manufacturers or distributors and do not reflect the opinion of the editorial team.



07
Dr Mirjam Kessler, VP Brand & Corporate Communications.

continuous innovation. And, responsibility for patients, for our partners, for science and for quality," says CEO Diego Gabathuler.

Since 2025, Geistlich has been shaping the future. The company is expanding its portfolio and tailoring its offerings even more precisely to the needs of distinct customer groups and market segments. Specialists, dental service organisations (DSOs), general practitioners, and emerging markets will benefit from increasingly





08
CCO Istvan Galo.

09
At the press conference during the symposium: CEO Diego Gabathuler.



11
Four kilos of paper: that's how much research was compiled on the Geistlich Bio-Gide® technology.



10
CSO Dr Mark Spilker.



12
At the IOS, Geistlich launched the new collagen membrane Geistlich Bio-Gide® Forte.

*The articles in this category are provided by the manufacturers or distributors and do not reflect the opinion of the editorial team.



13
Celebrating 175 years of company history stands for reliability, quality, and responsibility.

14
The Geistlich team at the press conference held during the symposium.





15
Dialogue between practitioners and experts.

customised solutions. By 2035, Geistlich aims to improve the quality of life of more than 80 million people through dental regeneration. A robust pipeline signals yet another transformation in the company's history, driven by the introduction of new technologies, new brands, and new channels.

Promoting young talent

To support the next generation, Geistlich has launched two additional development programmes. With the "Next Generation Round Table," a total of 67 selected, talented clinicians aged 30 to 42 from around the world will begin a three-year training programme this year. In addition, the "Rising Stars Case Competition" recognised outstanding achievements in clinical practice on the IOS stage, such as Viraj Patel (UK) on the use of Allodyn® with and without REGENFAST® in a split-mouth comparison, Lorenzo Fiscalini (Switzerland) on the integration of Yxoss CBR® and REGENFAST® in bone regeneration in the anterior region, and Roberto Ledergerber (Ecuador) on innovative approaches to tooth splitting and periodontal regeneration.

Geistlich Pharma AG
www.geistlich.com

Watch here the Geistlich Bio-Gide® Forte handling

*The articles in this category are provided by the manufacturers or distributors and do not reflect the opinion of the editorial team.